Safety of sodium‐glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta‐analysis
Abstract Sodium–glucose cotransporter‐2 inhibitors (SGLT2is) reduce morbidity and mortality for heart failure (HF) patients and are recommended as cornerstones for their medical therapy. Utilization in clinical practice remains low for multiple reasons, one of which may be adverse events. We investi...
Main Authors: | Hamidreza Soleimani, Behrad Saeedian, Yeganeh Pasebani, Nastaran Babajani, Amirreza Pashapour Yeganeh, Pegah Bahirai, Hossein Navid, Ahmad Amin, Marc D. Samsky, Micheal G. Nanna, Kaveh Hosseini |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-04-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.14633 |
Similar Items
-
Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure
by: Dominik Kurczyński, et al.
Published: (2022-07-01) -
Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
by: Al-Anood Al-Shamasi, et al.
Published: (2021-11-01) -
New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
by: Juexing Li, et al.
Published: (2022-09-01) -
Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study
by: Yuto Saijo, et al.
Published: (2023-11-01) -
The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword?
by: Ayami Naito, et al.
Published: (2024-01-01)